Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:80202 |
Name | adenoid cystic carcinoma |
Definition | An adenocarcinoma that is characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer pharynx cancer oropharynx cancer tonsil cancer adenoid cystic carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | LY3039478 | adenoid cystic carcinoma | not applicable | detail... |
Unknown unknown | Dovitinib | adenoid cystic carcinoma | not applicable | detail... |
NOTCH1 I1680N | Brontictuzumab | adenoid cystic carcinoma | predicted - sensitive | detail... |
NOTCH1 S1004L | Brontictuzumab | adenoid cystic carcinoma | no benefit | detail... |
NOTCH1 L1600Q NOTCH1 S2467fs | Brontictuzumab | adenoid cystic carcinoma | predicted - sensitive | detail... |
FBXW7 W606* NOTCH1 L1600Q NOTCH1 V1721G NOTCH1 S2467fs | Brontictuzumab | adenoid cystic carcinoma | predicted - resistant | detail... |
FBXW7 W606* NOTCH1 L1600Q NOTCH1 V1721G NOTCH1 S2467fs | Sunitinib | adenoid cystic carcinoma | no benefit | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00770263 | Phase I | Erlotinib + Temsirolimus | Erlotinib and Temsirolimus for Solid Tumors | Completed | USA | 0 |
NCT02098538 | Phase II | Regorafenib | Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma | Active, not recruiting | USA | 0 |
NCT02780310 | Phase II | Lenvatinib | Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma | Active, not recruiting | USA | 0 |
NCT02783300 | Phase I | GSK3326595 | Dose Escalation Study of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma (NHL) | Recruiting | USA | CAN | 2 |
NCT03087019 | Phase II | Pembrolizumab | Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | Active, not recruiting | USA | 0 |
NCT03172624 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer | Active, not recruiting | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Recruiting | USA | 3 |
NCT03691207 | Phase II | BMS-906024 | A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY) | Recruiting | USA | CAN | 4 |
NCT03990571 | Phase II | Avelumab + Axitinib | Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | Recruiting | USA | 0 |
NCT04209660 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers | Recruiting | USA | 0 |